TY - JOUR
T1 - Comparative Immunogenicity of 7 and 13-Valent Pneumococcal Conjugate Vaccines and the Development of Functional Antibodies to Cross-Reactive Serotypes
AU - Grant, Lindsay R.
AU - O'Brien, Sarah E.
AU - Burbidge, Polly
AU - Haston, Mitch
AU - Zancolli, Marta
AU - Cowell, Lucy
AU - Johnson, Marina
AU - Weatherholtz, Robert C.
AU - Reid, Raymond
AU - Santosham, Mathuram
AU - O'Brien, Katherine L.
AU - Goldblatt, David
N1 - Funding Information:
KOB, LRG, RCW and RR have research grant support from GlaxoSmithKline (GSK). KOB has received honoraria for participation in external expert advisory committees on pneumococcal vaccines convened by Merck, Sanofi-Pasteur, and GSK. MS has research grant support from GSK and has received honoraria for participation in external expert advisory committees on pneumococcal vaccines convened by GSK. DG has received honoraria for participation in external expert advisory committees on pneumococcal vaccines convened by Pfizer, GSK and Merck. DG’s laboratory performs contract research for Merck and GSK. No other authors report a conflict of interest. This does not alter the authors’ adherence to all of the PLOS ONE policies on sharing data and materials.
PY - 2013/9/23
Y1 - 2013/9/23
N2 - Background:Protection against disease or colonization from serotypes related to those in pneumococcal conjugate vaccines (i.e. cross-protection) vary by serotype; the basis for this variation is not understood. The 13-valent pneumococcal conjugate vaccine (PCV13) replaced 7-valent conjugate (PCV7) in the USA in 2010 allowing assessment of PCV7 and PCV13 immunogenicity and functional cross-protection in vitro.Methods:Post-primary, pre-booster and post-booster sera from American Indian children receiving exclusively PCV7 or PCV13 were collected. IgG was measured by ELISA for 13 vaccine serotypes; functional antibody was assessed by opsonophagocytic killing assays for serotypes 6A/B/C and 19A/F.Results:Post-primary IgG geometric mean concentrations (GMC) for serotypes 4 and 9V were lower in PCV13 recipients while 19F GMCs were higher. Only 19F differences persisted after receipt of the booster dose. Functional antibody activity was higher among PCV13 recipients for 6A, 6C, 19A and 19F (p<0.04), and among PCV7 recipients for 6B (p = 0.01). Following PCV7, functional antibodies to 6A but not 19A were observed. High levels of 6C functional activity were seen after PCV13 but not PCV7.Conclusions:Functional antibody activity against 6A/B/C and 19A/F suggest that PCV13 is likely to control the 19A disease and 6C disease remaining despite widespread use of PCV7.
AB - Background:Protection against disease or colonization from serotypes related to those in pneumococcal conjugate vaccines (i.e. cross-protection) vary by serotype; the basis for this variation is not understood. The 13-valent pneumococcal conjugate vaccine (PCV13) replaced 7-valent conjugate (PCV7) in the USA in 2010 allowing assessment of PCV7 and PCV13 immunogenicity and functional cross-protection in vitro.Methods:Post-primary, pre-booster and post-booster sera from American Indian children receiving exclusively PCV7 or PCV13 were collected. IgG was measured by ELISA for 13 vaccine serotypes; functional antibody was assessed by opsonophagocytic killing assays for serotypes 6A/B/C and 19A/F.Results:Post-primary IgG geometric mean concentrations (GMC) for serotypes 4 and 9V were lower in PCV13 recipients while 19F GMCs were higher. Only 19F differences persisted after receipt of the booster dose. Functional antibody activity was higher among PCV13 recipients for 6A, 6C, 19A and 19F (p<0.04), and among PCV7 recipients for 6B (p = 0.01). Following PCV7, functional antibodies to 6A but not 19A were observed. High levels of 6C functional activity were seen after PCV13 but not PCV7.Conclusions:Functional antibody activity against 6A/B/C and 19A/F suggest that PCV13 is likely to control the 19A disease and 6C disease remaining despite widespread use of PCV7.
UR - http://www.scopus.com/inward/record.url?scp=84884504627&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84884504627&partnerID=8YFLogxK
U2 - 10.1371/journal.pone.0074906
DO - 10.1371/journal.pone.0074906
M3 - Article
C2 - 24086394
AN - SCOPUS:84884504627
SN - 1932-6203
VL - 8
JO - PloS one
JF - PloS one
IS - 9
M1 - e74906
ER -